New research published in Nature links clinical activity with HIF‑2a biology in advanced kidney cancer patients treated with casdatifan
A new study published in Nature links casdatifan, an investigational HIF-2a inhibitor, to improved clinical outcomes in metastatic clear cell renal cell carcinoma (ccRCC) patients. Deep suppression of serum EPO correlated with higher response rates and longer progression-free survival.